Abstract
To evaluate diagnostic performance of endorectal magnetic resonance (eMR) for diagnosing local recurrence of prostate cancer (PC) in patients with previous radical prostatectomy (RP) and to assess whether contrast-enhanced (CE)-eMR improved diagnostic accuracy in comparison to unenhanced study. Unenhanced eMR data of 72 male patients (mean of total PSA: 1.23 ± 1.3 ng/ml) with previous RP were interpreted retrospectively and classified either as normal or suspicious for local recurrence. All eMR examinations were re-evaluated also on CE-eMR 4 months after the first reading. Images were acquired on a 1.5-T system. These data were compared to the standard of reference for local recurrence: prostatectomy bed biopsy results; choline positron emission tomography results; PSA reduction or increase after pelvic radiotherapy; PSA modification during active surveillance. Sensitivity, specificity, predictive positive value, negative predictive value and accuracy were 61.4%, 82.1%, 84.4%, 57.5% and 69.4% for unenhanced eMR and 84.1%, 89.3%, 92.5%, 78.1% and 86.1% for CE-eMR. A statistically significant difference was found between accuracy and sensitivity of the two evaluations (χ2 = 5.33; p = 0.02 and χ2 = 9.00; p = 0.0027). EMR had great accuracy for visualizing local recurrence of PC after RP. CE-eMR improved diagnostic performance in comparison with T2-weighted imaging alone.
Similar content being viewed by others
References
Crawford ED (2003) Epidemiology of prostate cancer. Urology 62:3–12
Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96
Shibata A, Whittemore AS (1998) Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer I 93:1109–1110
Lu-Yao GL, Greenberg ER (1994) Change in prostate cancer incidence and treatment in USA. Lancet 343:251–254
Lu-Yao GL, Yao S (1997) Population-based study of long-term survival in patients with clinically localized prostate cancer. Lancet 349:906–910
Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517–23
Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H (2000) Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 164:101–105
Catalona WJ, Smith DS (1994) 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 152:1837–1842
Freedland SJ, Mangold LA, Walsh PC, Partin AW (2005) The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. J Urol 174:1276–1281
Kattan MW, Wheeler TM, Scardino PT (1999) Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17:1499–1507
Trapasso JG, deKernion JB, Smith RB, Dorey F (1994) The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152:1821–1825
Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM (1994) Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152 5 Pt 2):1850–1857
Polascik TJ, Oesterling JE, Partin AW (1999) Prostate specific antigen. a decade of discovery – what we have learned and where we are going. J Urol 162:293–300
Freedland SJ, Sutter ME, Dorey F, Aronson WJ (2003) Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Urology 61:365–369
Laufer M, Pound CR, Carducci MA, Eisenberger MA (2000) Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology 55:309–315
Amling CL, Bergstralh EJ, Blute ML, Slezak A, Zincke H (2001) Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cutpoint? J Urol 165:1146–1151
Scattoni V, Montorsi F, Picchio M et al (2004) Diagnosis of local recurrence after radical prostatectomy. BJU Int 93:680–688
Sella T, Schwartz LH, Swindle PW et al (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231:379–385
Kane CJ, Amling CL, Johnstone PA et al (2003) Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61:607–611
Cher ML, Bianco FJ Jr, Lam JS et al (1998) Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 160:1387–1391
Seltzer MA, Barbaric Z, Belldegrun A et al (1999) Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 162:1322–1328
Oyen RH, van Poppel HP, Ameye FE et al (1994) Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology 190:315–322
Lecouvet FE, Geukens D, Stainier A et al (2007) Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 25:3281–3287
Walsh JW, Amendola MA, Konerding KF, Tisnado J, Hazra TA (1980) Computed tomographic detection of pelvic and inguinal lymph-node metastases from primary and recurrent pelvic malignant disease. Radiology 137:157–166
Cimitan M, Bortolus R, Morassut S et al (2006) 18F-Fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33:1387–1398
Reske SN, Blumstein NM, Glatting G (2008) 11C-Choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 35:9–17
De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2003) 11C-Choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44:32–38
Yoshida S, Nakagomi K, Goto S, Futatsubashi M, Torizuka T (2005) 11C-Choline positron emission tomography in prostate cancer: primary staging and recurrent site staging. Urol Int 74:214–220
Silverman JM, Krebs TL (1997) MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. Am J Roentgenol 168:379–385
Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF (1999) Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 17:1155
Leventis AK, Shariat SF, Slawin KM (2001) Local recurrence after radical prostatectomy. Correlation of US features with prostatic fossa biopsy findings. Radiology 219:432–439
Goldenberg SL, Carter M, Dashefsky S, Cooperberg PL (1992) Sonographic characteristics of the urethrovesical anastomosis in the early post-radical prostatectomy patient. J Urol 147:1307–1309
Parra RO, Wolf RM, Huben RP (1990) The use of transrectal ultrasound in the detection and evaluation of local pelvic recurrences after a radical urological pelvic operation. J Urol 144:707–709
Abi-Aad AS, Macfarlane MT, Stein A, deKernion JB (1992) Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound. J Urol 147:952–955
Kapoor DA, Wasserman NF, Zhang G, Reddy PK (1993) Value of transrectal ultrasound in identifying local disease after radical prostatectomy. Urology 41:594–597
Foster LS, Jajodia P, Fournier G Jr, Shinohara K, Carroll P, Narayan P (1993) The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol 149:1024–1028
Kramer S, Gorich J, Gottfried HW et al (1997) Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol 70:995–999
Kotzerke J, Volkmer BG, Glatting G et al (2003) Intraindividual comparison of 11C-acetate and 11C-choline PET for detection of metastases of prostate cancer. Nuklearmedizin 42:25–30
Heinisch M, Dirisamer A, Loidl W et al (2006) Positron emission tomography/computed tomography with F18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng/ml? Mol Imaging Biol 8:43–48
Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN (2002) C11-Acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 29:1380–1384
Vees H, Buchegger F, Albrecht S (2007) 18F-Choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/ml) after radical prostatectomy. BJU Int 99:1415–1420
Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K, Möller P, Wiegel T, Kuefer R, Gschwend JE (2007) Evaluation of 11C-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 100:786–793
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cirillo, S., Petracchini, M., Scotti, L. et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 19, 761–769 (2009). https://doi.org/10.1007/s00330-008-1174-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-008-1174-8